Invex Therapeutics marks best day in over 2 years on FDA nod

Invex Therapeutics

19/08/2022 04:45

** Shares of Invex Therapeutics Ltd  IXC.AX  jump as much as
25% to A$0.700, its biggest intraday pct gain since May 22, 2020
    ** Biopharma Co received Investigation New Drug Application 
approval from U.S Food and Drug Administration for Presendin (https://bit.ly/3QZ5U2t)
    ** FDA also approved commencement for Presendin's IIH EVOLVE
Phase 3 clinical trial in U.S. for patients with Idiopathic
Intracranial Hypertension
    ** Co says IIH EVOLVE has being designed to meet
requirements for market approval of Presendin in Europe, United
Kingdom and Australia
    ** Shares at their highest since May 4
    ** Stock has fallen 20.6% this year, as of last close

 (Reporting by Echha Jain in Bengaluru)
 ((Echha.jain@thomsonreuters.com))